National Asset Management, Inc. Adamis Pharmaceuticals Corp Transaction History

National Asset Management, Inc.

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 21, 2023	SELL	$0.14 - $0.22 $210 - $330	-1,500 Reduced 6.98%	20,000 $3,000
Q3 2022 Nov 14, 2022	SELL	$0.24 - $0.54 $890 - $2,003	-3,710 Reduced 14.72%	21,500 $5,000
Q2 2021 Aug 10, 2021	BUY	$0.66 - $1.23 $455 - $848	690 Added 2.81%	25,210 $28,000
Q1 2021 May 13, 2021	SELL	$0.54 - $1.79 $7,020 - $23,270	-13,000 Reduced 34.65%	24,520 $24,000
Q4 2020 Feb 04, 2021	SELL	$0.4 - $1.01 $600 - $1,515	-1,500 Reduced 3.84%	37,520 $19,000
Q3 2020 Nov 09, 2020	BUY	$0.52 - $1.45 $780 - $2,175	1,500 Added 4.0%	39,020 $31,000
Q3 2019 Nov 12, 2019	BUY	$0.7 - $1.46 $6,020 - $12,556	8,600 Added 29.74%	37,520 $27,000
Q2 2019 Aug 05, 2019	SELL	$1.26 - $2.23 $1,260 - $2,230	-1,000 Reduced 3.34%	28,920 $38,000
Q1 2019 May 08, 2019	BUY	$2.02 - $3.22 $13,554 - $21,606	6,710 Added 28.91%	29,920 $64,000
Q3 2018 Nov 08, 2018	BUY	$2.25 - $4.8 $4,185 - $8,928	1,860 Added 8.71%	23,210 $82,000
Q2 2018 Oct 05, 2018	SELL	$3.2 - $4.7 $5,120 - $7,520	-1,600 Reduced 6.97%	21,350 $69,000
Q1 2018 May 15, 2018	BUY	$2.55 - $4.85 $1,275 - $2,425	500 Added 2.23%	22,950 $81,000
Q4 2017 Feb 15, 2018	BUY	$3.5 - $5.65 $78,575 - $126,842	22,450	22,450 $99,000

Ticker ADMP
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 149,983,008
Market Cap $73.5M
Description
Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy, opioid overdose, respiratory, and inflammatory disease in the United States. The company's product candidates comprise SYMJEPI epinephrine pre-filled syringe injectable products for use in the emerg...

Get notified when there are updates to the investment portfolio of National Asset Management, Inc., based on Form 13F filings with the SEC.

Stay updated on National Asset Management, Inc. with notifications on news.